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Although many risk factors could have causal association with endometrial cancer, they are also prone to residual confounding
or other biases which could lead to over- or underestimation. This umbrella review evaluates the strength and validity of
evidence pertaining risk factors for endometrial cancer. Systematic reviews or meta-analyses of observational studies
evaluating the association between non-genetic risk factors and risk of developing or dying from endometrial cancer were
identified from inception to April 2018 using PubMed, the Cochrane database and manual reference screening. Evidence was
graded strong, highly suggestive, suggestive or weak based on statistical significance of random-effects summary estimate,
largest study included, number of cases, between-study heterogeneity, 95% prediction intervals, small study effects, excess
significance bias and sensitivity analysis with credibility ceilings. We identified 171 meta-analyses investigating associations
between 53 risk factors and endometrial cancer incidence and mortality. Risk factors were categorised: anthropometric indices,
dietary intake, physical activity, medical conditions, hormonal therapy use, biochemical markers, gynaecological history and
smoking. Of 127 meta-analyses including cohort studies, three associations were graded with strong evidence. Body mass
index and waist-to-hip ratio were associated with increased cancer risk in premenopausal women (RR per 5 kg/m2 1.49; CI
1.39–1.61) and for total endometrial cancer (RR per 0.1unit 1.21; CI 1.13–1.29), respectively. Parity reduced risk of disease
(RR 0.66, CI 0.60–0.74). Of many proposed risk factors, only three had strong association without hints of bias. Identification
of genuine risk factors associated with endometrial cancer may assist in developing targeted prevention strategies for women
at high risk.
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Introduction
Endometrial cancer is the most common gynaecological can-
cer and the second most common female malignancy, after
breast cancer, in the developed world.1 In 2012, the number
of new cases and deaths due to endometrial cancer worldwide
was 319,605 and 76,160 respectively.1 The age-standardised
incidence and mortality rates from endometrial cancer have
been rising steadily in most developed countries over the
period 1978–2013, which has been attributed mainly to life-
style factors (e.g., the obesity and diabetes epidemic), increas-
ing age and socioeconomic-driven changes to reproductive
factors such as parity.2 The use of uterine-sparing treatments
for dysfunctional menstrual bleeding has also resulted in a
reduced number of hysterectomies performed early in life.3
Endometrial cancer incidence is predicted to continue to rise
in the coming decades, in particular among low and middle-
income countries.
Several non-genetic risk factors have been associated with
an increased risk of endometrial cancer, particularly for the
most prevalent histological subtype endometrioid endometrial
adenocarcinoma, which include obesity, physical inactivity,
excess exogenous oestrogen, insulin resistance,4 and tamoxifen
use after breast cancer,5–9 whereas daily coffee consumption
has been shown to be inversely associated with endometrial
cancer.10–15 Although many of the reported risk factors could
have a causal association with endometrial cancer, they could
also be over- or underestimated due to residual confounding
or other biases, which are common in the epidemiological
literature.16–18 Umbrella reviews can systematically appraise
evidence in the published literature by evaluating meta-
analyses of multiple putative risk factors on multiple outcomes.
Recent umbrella reviews across a broad spectrum of disease
outcomes have concluded that only a minority of several pub-
lished associations have robust data without hints of bias; these
included associations between adiposity,19 diabetes mellitus
and cancer incidence and mortality,20 among others.21–24
We performed an umbrella review of systematic reviews
and meta-analyses to investigate the strength and validity of
the associations between non-genetic risk factors and the risk
of developing or dying from endometrial cancer.
Methods
Literature search and eligibility criteria
We searched PubMed and the Cochrane database of system-
atic reviews from inception to April 2, 2018 for systematic
reviews and meta-analyses of observational studies that inves-
tigated the association between non-genetic risk factors and
risk of endometrial cancer development and death
(Supporting Information). We further hand-searched the cita-
tions of the retrieved eligible papers to identify additional
publications that might have been missed during the initial
search and the proceedings of relevant conferences for unpub-
lished data. In this umbrella review the primary analysis
focused on cohort studies, representing the best available
evidence among observational studies. Sensitivity analyses
were conducted including case–control studies.
Inclusion and exclusion criteria
We included systematic reviews with or without meta-analyses
of observational epidemiological studies in humans that
assessed lifestyle and environmental (non-genetic) risk factors
and endometrial cancer incidence or mortality. We excluded
studies where endometrial cancer incidence and mortality
were not the primary outcomes, studies with benign endome-
trial pathologies as the primary outcomes of interest (such as
fibroids or endometrial polyps), studies exploring the impact
of genetic factors as well as studies assessing prognostic risk
factors among women diagnosed with endometrial cancer
(Supporting Information Figure 1).25–53 We further excluded
narrative reviews and meta-analyses that had only one study,
did not report the necessary study-specific data including the
relative risk (RR) and 95% confidence intervals (CI) or the
number of endometrial cancer cases and controls or total
population.14,54–71 Where two or more meta-analyses examined
the exact same association, we chose the largest meta-analysis
to avoid duplicate assessment of the same primary studies; the
concordance between included and duplicate meta-analyses
was explored in a sensitivity analysis (Supporting Information).
Evaluating the strength of evidence by grading criteria
The association of each risk factor with endometrial cancer
was graded as strong, highly suggestive, suggestive or weak
evidence. To be included in the ‘strong evidence’ group, the
meta-analysis had to present a p-value of the random effects
model smaller than 10−6, a threshold that might substantially
reduce false positive findings,72–74 include more than 1000
cancer cases, have an I2 for heterogeneity less than 50%, the
95% prediction intervals should exclude the null value, and
there should be no indication of small study effects or excess
significance bias. Similarly, to satisfy the criteria for inclusion
into the ‘highly suggestive’ group, meta-analyses needed a ran-
dom effects p value smaller than 10−6, include more than
1000 cases, and have a nominally statistically significant larg-
est study (i.e. p < 0.05) in the meta-analysis. A ‘suggestive’
association should meet the after criteria: random effects P
smaller than 10−3, and more than 1000 cases. Any remaining
meta-analyses where the p-value of the random effects model
was nominally statistically significant were considered to pre-
sent weak evidence. Sensitivity analyses were conducted after
further applying the credibility ceiling threshold analysis to
account that a single observational study cannot give more
than a maximum certainty, c% (credibility ceiling), that the
true effect size is in a different direction from the one sug-
gested by the point estimate75 (Supporting Information).
Evaluation of the quality of included meta-analyses
We assessed the strength and quality of all included meta-
analyses using the AMSTAR tool, which uses 11 criterion
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items to measure the methodological quality of systematic
reviews.76 If the specific criterion is met, one point is allo-
cated. An overall score relating to review quality is then calcu-
lated using the sum of the individual scores. A review scoring
above 8 is considered high quality, 4 to 7 is a review of mod-
erate quality and below 4 is low quality.
The search algorithms, the data extraction process and the
full description of the individual criteria used for grading can
be found in the Supporting Information. All statistical ana-
lyses were performed using Stata version 13 (College Station,
TX) (StatCorp 2013), and all p values were two tailed.
Patient involvement
We did not involve patients in our study. The results will be
disseminated to the general public through public presenta-
tions and authors’ involvement in different charities.
Results
Characteristics of meta-analyses
We identified 61 eligible publications that included 171 meta-
analyses of 1354 individual study estimates (Supporting Infor-
mation Figure 1).13,77–136 Of these, 604 studies were cohort
(45%), whereas 750 (55%) were case–control studies, and one
was a pooled analysis of cohort and case–control studies. In
all included meta-analyses, there were two to 42 study esti-
mates combined per meta-analysis with a median of five. The
median number of cases and total population in each meta-
analysis was 3271 and 265,375 respectively. The lowest num-
ber of cases in a meta-analysis was 66 and the highest was
37,423, whereas the smallest total population was 709 and
highest total population was 6,445,255. In 145 out of the
171 included meta-analyses, there were more than 1000 cases
of endometrial cancer.
A total of 53 risk factors were examined in the 171 meta-
analyses, which belong to eight broad categories: seven
anthropometric indices (i.e. body mass index (BMI), waist to
hip ratio (WHR), waist circumference (WC), weight gain
(WG), weight, hip circumference and height); 19 dietary fac-
tors (e.g. dairy, fish, fruit, isoflavones, meat, nut, vegetable,
alcohol, tea, coffee, acrylamide, cholesterol, fat, fatty acids,
type of dietary intake, fibre, folate, glycaemic load and glycae-
mic index); two risk factors including physical activity and
sedentary behaviour (recreational, occupational and total sit-
ting time); six risk factors associated with pre-existing medical
conditions or interventions (i.e. presence of metabolic
syndrome, diabetes mellitus, hypertension, systemic lupus ery-
thematous, polycystic ovarian syndrome and bariatric sur-
gery); nine factors related to medication or hormonal therapy
use (i.e. acetaminophen (paracetamol), aspirin, statin, metfor-
min, bisphosphonate, non-steroidal anti-inflammatory drug,
ovary stimulating drugs for subfertility, oral contraceptives
and intrauterine devices); four biomarkers (i.e. adiponectin,
leptin, adiponectin to leptin ratio and insulin/c-peptide level);
five risk factors related to past gynaecological history (i.e. age
at menarche, age at last birth, breastfeeding, fertility treatment
and parity) and smoking.
Of the 171 meta-analyses, we identified 127 meta-analyses
that included at least 2 cohort studies assessing 42 risk factors.
Two of the 127 meta-analyses reported on endometrial cancer
mortality, the remainder on endometrial cancer incidence.
These are presented in Supporting Information Tables S1 and
S2. Critical appraisal of the evidence in this review focuses on
associations from cohort studies, which constitute the best
available evidence among observational studies.
Summary effect size
With p < 0.05 taken as the threshold of statistical significance,
the summary fixed effects estimates were significant in 68 out
of the 127 meta-analyses of cohort studies (54%), whereas the
summary random effects were significant in 56 meta-analyses
(44%) (Supporting Information Table S1). At p < 0.001,
54 (43%) and 43 (34%) meta-analyses produced significant
summary results using the fixed and random effects model,
respectively. At a more stringent threshold of statistical
significance (p < 10−6), summary fixed effects estimates were
significant in 35 (28%) meta-analyses and summary random
effects were significant in 22 (17%) meta-analyses. Of the
20 meta-analyses with strongly statistically significant sum-
mary random effect estimates, 18 reported an increased risk
of endometrial cancer incidence or mortality for the after risk
factors: BMI, hip circumference, height, waist circumference,
WHR, weight gain, weight, diabetes mellitus and metabolic
syndrome. An inverse association with endometrial cancer
incidence was suggested for coffee intake and parity
(Supporting Information Table S1). The magnitude of the
observed summary random effect estimates ranged from a risk
ratio of 0.39 to 3.10, with 64% of the estimates falling between
0.80 and 1.20 (Fig. 1).
The association of the largest study included in each meta-
analysis was nominally statistically significant in 50 meta-
analyses (39%), and the relative risks of the largest studies
were more conservative than the summary random effects in
54 (43%) meta-analyses (Supporting Information Table S1).
Heterogeneity between studies
The Q test for heterogeneity was significant at p ≤ 0.10 in
44 out of 127 meta-analyses (35%). Large heterogeneity
(I2 = 50–75%) was found in 27 (21%) meta-analyses and very
large heterogeneity (I2 > 75%) in 16 (13%) meta-analyses for
ten exposures, including alcohol intake, bariatric surgery, dia-
betes, BMI per 5 kg/m2, BMI (overweight vs. normal), fertility
treatment, glycaemic load intake, physical activity, and for
Western-style and healthy-style dietary intake pattern
(Supporting Information Table S2).
Small study effects
Small study effects (Egger’s test p value <0.10 and where more
conservative effects in the largest study of a meta-analysis
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compared to the summary random effects estimate were
recorded) were found to be present in seven meta-analyses for
risk factors including age at menarche (per two-year delay in
menarcheal age), age at menarche (highest vs. lowest), BMI
per 5 kg/m2 (never HRT use, postmenopausal), dietary mono-
unsaturated fatty acid and acrylamide intake, walking time,
and coffee intake (heavy vs. non-drinker) (Supporting Infor-
mation Table S2).
Excess significance
Fifteen meta-analyses had evidence of excess significance bias
using the largest study estimate as the plausible effect size
(p < 0.10). These included BMI (in young adulthood, per
5 kg/m2), weight gain (per 5 kg), weight (per 5 kg), coffee
intake (heavy vs. non-drinker and per 1 cup/day), monounsat-
urated fatty acid intake (highest vs. lowest), unhealthy and
western style dietary intake (highest vs. lowest), alcohol intake
among postmenopausal women and beer and wine intake (per
10 g/day), aspirin intake, leisure time physical activity (per one
hour/week), physical activity (highest vs. lowest in women with
BMI ≥ 25), bisphosphonate use (ever vs. never) and age at
menarche (per two-year delay in menarcheal age). When either
summary fixed, or random effects estimates were alternatively
used as plausible effect sizes, excess significance bias was addi-
tionally identified for alcohol intake (high vs. low drinkers and
intake from liquor) (Supporting Information Table S2).
Quality assessment
We assessed the methodological quality of 61 publications that
included 171 meta-analyses of observational studies, using the
AMSTAR tool (Supporting Information Table S3). The World
Cancer Research Fund Continuous Update Project report116
was not included in this assessment, having already been sub-
jected to extensive peer review processes. Only 12 meta-analyses
(20%) provided “a priori” published protocols or ethics
approval statements. There were at least two independent data
extractors and consensus procedures in place where disagree-
ments occurred in only 24 (40%) meta-analyses. Most meta-
analyses performed a comprehensive literature search (80%),
used appropriate methods to combine the findings (95%),
assessed likelihood of publication bias (75%), and provided the
characteristics of included studies (98%). Twenty-eight meta-
analyses (46%) assessed the scientific quality of included studies
and used this assessment to appropriately formulate conclu-
sions (44%). Only two of the included meta-analyses indicated
the source of funding for both original studies and meta-analy-
sis. In total, two thirds of the meta-analyses (69%) scored
between four to seven points and were considered of moderate
quality, nine (15%) scored at least eight points and were consid-
ered to be high quality and ten meta-analyses (16%) scored
three or less points and were considered low in quality. Low
quality meta-analyses as per AMSTAR investigated the follow-
ing exposures: dietary intake of fruit and vegetables, dietary
lipid intake, dietary glycaemic load and index intake, acrylam-
ide intake, aspirin use, intrauterine device use, systemic lupus
erythematous, breastfeeding, age at last birth and diabetes.
Grading the evidence
Each of the risk factors identified as being associated with
endometrial cancer incidence or mortality was graded into
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Figure 1. The association between summary random effects estimates and inverse of variance in meta-analyses, stratified by type of
exposure-outcome pair.
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four groups according to the strength of reported evidence in
cohort studies: strong, highly suggestive, suggestive or weak
evidence (Table 1). Detailed explanation of the assessment cri-
teria is presented in Supporting Information Table S4 (for
cohort studies only), while the results for both cohort and case–
control studies are shown in Supporting Information Table S5.
Only three out of 127 meta-analyses (2.4%) fulfilled the
criteria of strong evidence of an association with endometrial
cancer incidence. BMI was associated with an increased risk
of endometrial cancer in premenopausal women (RR per
5 kg/m2 1.49; 95% CI 1.39–1.61). WHR was associated with
an increased risk of endometrial cancer overall (RR per 0.1
unit 1.21; 95% CI 1.13–1.29). Parity was associated with
reduced risk of endometrial cancer (RR 0.66, 95% CI
0.60–0.74) compared to nulliparous women (Table 1 and Sup-
porting Information Table S4). These three meta-analyses
scored five, six and six points on the AMSTAR assessment,
respectively, and were hence considered to be of moderate
methodological quality.
Thirteen meta-analyses (10.2%) presented highly suggestive
evidence and evaluated associations between risk of endome-
trial cancer and anthropometric indices (n = 10) and diabetes
mellitus (n = 3) (Table 1 and Supporting Information Table
S4). One meta-analysis graded as highly suggestive, between
diabetes and endometrial cancer,92 scored eight points on
AMSTAR assessment, and was considered to be of high meth-
odological quality. The remaining 12 were considered to be of
moderate or low quality. Suggestive evidence was found for
14 meta-analyses (11.0%) and weak evidence for 26 meta-
analyses (20.5%).
Sensitivity analyses
When both cohort and case–control studies were included in
the analysis (Supporting Information Table S5), four addi-
tional risk factors presented strong evidence for an inverse
association with endometrial cancer incidence: occupational
physical activity (highest versus lowest category, RR 0.81, 95%
CI 0.76–0.87), physical activity (all types, highest versus lowest
category, RR 0.80, 95% CI 0.74–0.85), smoking (case–control
studies only, RR 0.72, 95% CI 0.66–0.79) and smoking among
postmenopausal women (RR 0.71, 95% CI 0.65–0.78). These
associations provided only suggestive evidence when cohort
studies alone were included. The strong association between
parity and decreased endometrial cancer risk was downgraded
to highly suggestive evidence (RR 0.69, 95% CI 0.65–0.73)
when both cohort and case–control studies were evaluated
due to the observed high between-study heterogeneity
(Supporting Information Table S5).
We found that 44 out of 127 meta-analyses (35%) of
cohort studies retained nominal statistical significance
(p < 0.05) with a credibility ceiling of 0%. With ceilings of 10%,
15% and 20%, 31 (24%), 18 (14%) and 8 (6%) meta-analyses
remained statistically significant, respectively (Supporting
Information Table S6). All three of the risk factors with strong
evidence (BMI per 5 kg/m2 for premenopausal endometrial
cancer, WHR per 0.1 units and parity) remained nominally sta-
tistically significant until a 17% credibility ceiling was applied.
The 11 risk factors found to have highly suggestive evidence
remained nominally statistically significant until a 13% credibil-
ity ceiling was applied (Supporting Information Table S6).
We identified more than one published meta-analysis
assessing the same risk factors and incidence or mortality of
endometrial cancer for 39 of the risk factors identified. For all
duplicate meta-analyses (n = 33), there was agreement on the
direction, magnitude and statistical significance of the sum-
mary associations between the included and excluded meta-
analyses (Supporting Information Table S7). When the same
evidence grading criteria were applied to these duplicate
meta-analyses, the grading was similar in the majority of com-
parisons. Most of the excluded duplicate meta-analyses also
had the same or weaker evidence grading (n = 17 and
16, respectively) compared to included meta-analyses. Of the
remaining excluded duplicate studies, coffee intake (n = 2
meta-analyses) and intrauterine device (IUD) use (n = 1) met
criteria for a strong association. Glycaemic load intake (n = 1)
met suggestive and total fat intake (n = 1) met weak evidence.
The cohort studies from the excluded meta-analyses for coffee
intake10–12 were all included in the newer meta-analyses.13,116
The other excluded meta-analyses also had fewer cohorts
included, despite being published more recently.15,137 Upon
further comparison between the two and further investigation
of the original studies, the excluded meta-analysis also
reported some incorrect relative risks in the analysis. For IUD
use, the included meta-analysis was a pooled analysis of
17 studies (four cohort, 13 case–control) from the Epidemiol-
ogy of Endometrial Cancer Consortium, whereas the smaller
excluded meta-analysis included only ten case–control studies.
All the studies from the duplicate meta-analysis for glycaemic
load intake (eight studies, six cohorts; suggestive evidence)
were all found in the larger more recent included meta-
analysis (11 studies, seven cohorts; weak evidence). Despite
reaching the suggestive evidence category, the older meta-
analysis had only one statistically significant study from the
eight included.
Discussion
Main findings and interpretation in light of existing
evidence
This umbrella review, containing data extracted from
171 meta-analyses of which 127 meta-analyses included at
least two cohort studies, suggests that only three meta-
analyses presented strong evidence for association with endo-
metrial cancer incidence, reflecting strongly statistically sig-
nificant results and no suggestion of biases. BMI and WHR
were positively associated with endometrial cancer among
premenopausal women and overall, respectively, whereas
parity was associated with reduced risk of total endometrial
cancer. Associations between diabetes mellitus (type one or
Raglan et al. 1723
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Table 1. Summary of evidence grading for meta-analyses of risk factors associated with endometrial cancer incidence or mortality—cohort
studies only*
Evidence Criteria used Decreased Risk Increased Risk
Strong p < 10–6k; >1000 cases;
I2 < 50%; no small
study effects¶;
prediction interval
excludes the null
value; no excess
significance bias†
Past gynaecological history Anthropometric indices
Parity: parous vs. nulliparous BMI per 5 kg/m2: premenopausal
Waist-to-hip ratio: per 0.1 units
Highly
Suggestive
p < 10–6k; >1000 cases;
p < 0.05 of the largest
study in a
meta-analysis
None Anthropometric indices
BMI iya: per 5 kg/m2
BMI per 5 kg/m2 increment
BMI per 5 kg/m2: Type II
BMI per 5 kg/m2: postmenopausal
BMI per 5 kg/m2: Type I
BMI: > 30 vs. < 25
Height: per 10 cm
Waist circumference: per 10 cm
Weight gain: per 5 kg
Weight: per 5 kg
Pre-existing medical conditions
Diabetes mellitus (T1/T2): present vs.
absent (HR)
Diabetes mellitus (T1/T2): present vs.
absent (IRR)
Diabetes mellitus (T1/T2): present vs.
absent (SIR)
Suggestive p < 10–3k; >1000 cases Dietary intake Physical activity and sedentary
behaviour
Coffee intake: highest vs. lowest category Sedentary behaviour: highest vs. lowest
category
Coffee intake: per 1 cup/day Pre-existing medical conditions and
interventions
Physical activity and sedentary behaviour Hypertension
Occupational physical activity: highest vs.
lowest category
Diabetes mellitus (T1/T2): present vs.
absent (RR)
Physical activity: highest vs. lowest category
Past gynaecological history
Age at last birth: per 5-year increment
Age at menarche: delay in menarcheal age, per
2-year delay
Age at menarche: highest vs. lowest category
Use of medical/hormonal therapy
Metformin use: ever vs. never
Oral contraceptive: ever vs. never use
Smoking
Smoking: ever vs. never**
Smoking: ever vs. never, postmenopausal
Weak p < 0.05k Dietary intake Anthropometric indices
Animal fat intake: per 10 g/1000 kcal BMI: per 5 kg/m2, ever HRT
Animal-based fat intake: per 30 g increase a
day
BMI: per 5 kg/m2, never HRT
Carbohydrate intake: per 100 g/day BMI: > 25 vs. < 25
Decaffeinated coffee intake: per 1 cup/day BMI: per 5 kg/m2, mortality
(Continues)
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type two), height and other anthropometric indices (i.e. BMI
in young adulthood, waist circumference and weight gain) with
endometrial cancer were graded with highly suggestive evidence.
Obesity and endometrial cancer
The majority of meta-analyses (11/17, 64.7%) studying adi-
posity indices in relation to endometrial cancer incidence and
mortality were supported by strong or highly suggestive evi-
dence. Our evidence grading largely agreed with the World
Cancer Research Fund Continued Update Project in 2013,116
where body fatness was deemed to have a ‘convincing causal
relationship’ with endometrial cancer. Similarly, the Interna-
tional Agency for Research on Cancer recently deemed adi-
posity to be causal for endometrial cancer.138 Furthermore,
our findings are in partial agreement with recent Mendelian
Randomisation studies, where genetically elevated BMI, but
not WHR, was found to be causally associated with endome-
trial cancer risk.139,140 The mechanisms that may underlie the
association of obesity with endometrial cancer are not fully
characterised but likely include higher oestrogen levels in
postmenopausal women, hyperinsulinaemia and a chronic
inflammatory state.4,8,19,141,142 In our review, the evidence for
an association between BMI and endometrial cancer was
strong for premenopausal cancer, but was highly suggestive
for postmenopausal disease due to large between-study het-
erogeneity, which could be due to a stronger association
observed between BMI and endometrial cancer among never-
users than among ever-users of HRT (RR 1.90, 95% CI
1.56–2.30, and RR 1.18, 95% CI 1.07–1.31).78 However, the
analyses by HRT use had fewer than 1000 incident cases and
were both classified as weak evidence.
Parity and endometrial cancer
We found strong evidence for a 40% reduction in endometrial
cancer incidence among parous compared to nulliparous
women. A large meta-analysis of 69,681 participants including
10 prospective studies, 35 case–control studies and one pooled
analysis suggested a non-linear inverse relationship between
parity and endometrial cancer risk.106 Hormonal changes dur-
ing pregnancy may explain this association, usually charac-
terised by a shift to greater progesterone production with
protective effects on the endometrium. The impact on the
timing of endometrial carcinogenesis or for different histologi-
cal subtypes is less well understood.
Diabetes and endometrial cancer
There was highly suggestive evidence that diabetes mellitus
increases the risk of endometrial cancer, although the association
Table 1. Continued
Evidence Criteria used Decreased Risk Increased Risk
Fibre intake: per 10 g/day Hip circumference: per 10 cm
Healthy dietary intake: highest vs. lowest
category
Weight gain: per 5 kg, ever HRT
Monounsaturated fatty acid intake: highest vs.
lowest category
Weight gain: per 5 kg, never HRT
Total fat intake: per 30 g increase a day Dietary intake
Physical activity and sedentary behaviour Glycaemic load intake: highest vs.
lowest category, obese
Leisure time physical activity: per 1 h/week Glycaemic load intake: per 50 units/day
Pre-existing medical conditions and
interventions
Western style pattern dietary intake:
highest vs. lowest
Bariatric surgery: yes vs. no Pre-existing medical conditions
Use of medical/hormonal therapy Diabetes mellitus (T1/T2): present vs.
absent, mortality
Bisphosphonate use: ever vs. never Metabolic syndrome: present vs. absent
Past gynaecological history Past gynaecological history
Breastfeeding: longest vs. shortest duration IVF done: ever vs. never
Smoking
Smoking: per 20 cigarettes/day increment**
Abbreviations: BMI, body mass index; BMI iya, Body mass index in young adulthood; EC, endometrial cancer; ECM, endometrial cancer mortality; HR,
hazard ratio; HRT, hormone replacement therapy; IRR, incidence rate ratio; IVF, in-vitro fertilisation; RR, relative risk; SIR, standardised incidence ratio;
T1 T2, Type 1 or Type 2 diabetes mellitus.
*only meta-analyses meeting at least weak grade of evidence listed.
**only prospective studies were included.
kp indicates the p values of the meta-analysis random effects model.
¶Small study effect is based on the p value from the Egger’s regression asymmetry test (p > 0.1) where the random effects summary estimate was larger
compared to the point estimate of the largest study in a meta-analysis.
†Based on the p value (p > 0.1) of the excess significance test using the largest study (smallest standard error) in a meta-analysis as the plausible effect
size.
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with mortality was weak. Our analysis was in line with a previ-
ously published umbrella review by Tsilidis and colleagues that
reported a summary random effects estimate of 1.97 (1.71–2.27)
for endometrial cancer incidence in diabetic patients.20,143
Hyperinsulinaemia, which is a common phenomenon prior to
diabetes onset, likely has a causal association with endometrial
cancer,4,140 either through direct mitogenic effects or possibly by
increasing the levels of bioavailable oestrogen through a reduc-
tion in sex hormone binding globulin (SHBG) levels.
Additional risk factors for endometrial cancer
There was highly suggestive evidence that adult attained
height was associated with increased risk of endometrial can-
cer. This finding was in partial agreement with the 2013
World Cancer Research Fund Continuous Update Project
(WCRF CUP) report judgement as ‘limited-suggestive’.116
More recent data from Aune et al. with six additional studies
also found height to be significantly associated with endome-
trial cancer risk (RR 1.15, 95% CI 1.09–1.22).77 Although it
seems biologically improbable that increased height would
directly modify endometrial cancer risk, height may act as a
marker for genetic and environmental factors affecting
women’s growth from pre-conception to growth comple-
tion.116 There was suggestive evidence that smoking reduced
the risk of endometrial cancer in cohort studies, although the
evidence became strong when case–control studies were
included.107 The majority of the published cohort studies
showed a reduction in risk of endometrial cancer among cur-
rent or former smokers compared to never smokers.144–153 A
mechanistic link between an anti-oestrogenic effect of smok-
ing and endometrial cancer risk has been suggested but has
limited direct evidence.154,155 There was suggestive evidence to
indicate that physical activity (any type or occupational) was
inversely associated with endometrial cancer. This was in
agreement with the WCRF report, which found probable
causal evidence for an inverse association between physical
activity and endometrial cancer.116 The association between
sedentary behaviour and endometrial cancer was supported
by suggestive evidence in agreement with the WCRF report.116
Our findings provided only suggestive evidence that coffee
intake decreases the risk of endometrial cancer mainly due to
evidence of excess significance bias, which was concordant with
the WCRF CUP report and results from another recent review
that graded the evidence for an association as probable.116,156
Two further risk factors, late age at last birth and metformin
use, also revealed suggestive evidence for a decrease in endome-
trial cancer risk. Potential biologically plausible mechanisms for
why late age at last birth may protect against endometrial can-
cer include prolonged progesterone exposure during pregnancy
being particularly beneficial in women of older age and the
probability of fewer anovulatory cycles in older women who
have become pregnant.124,157 Hypertension, despite adjustment
in the meta-analysis for smoking, BMI, oral contraceptive use
and parity, was the final risk factor identified within the
suggestive evidence category as increasing the risk of endome-
trial cancer. When both cohort and case–control studies were
considered, hypertension had a highly suggestive association
with endometrial carcinogenesis. The biological mechanism for
this association remains unclear, although it has been suggested
that chronic hypertension promotes cellular senescence and
inhibition of apoptosis.158,159
Strengths and weaknesses
This umbrella review presents the most comprehensive critical
appraisal of published associations between risk factors and
the risk of developing or dying from endometrial cancer.
Categorisation of this evidence was based on a wide range of
statistical tests and sensitivity analyses aimed to assess evi-
dence strength and validity. The criteria selected to grade each
meta-analysis by evidence level (i.e. strong, highly suggestive,
suggestive or weak) is a transparent and systematic way of
evaluating the strength of evidence in the literature.
Nevertheless, possible limitations and caveats should be
considered. This review relies on literature searches conducted
by the original authors and the results of already published
systematic reviews and meta-analyses. Although it is possible
that some studies were missed in the original searches, it is
unlikely that this has impacted our results, as the assessment
of duplicate meta-analyses led to similar results. The statistical
tests we used to explore presence of bias can only offer hints
of bias, but do not prove its definitive presence or its exact
source. However, our estimates are likely to be conservative,
as a negative test for bias does not exclude the potential for it
being present. Furthermore, the number of studies showing
separate results by pre- and post-menopausal women was low.
Analyses stratified by menopausal status could therefore not
be conducted other than for BMI, weight gain and smoking,
which may miss important exposures for a cancer type that is
hormonally driven and is most commonly diagnosed in post-
menopausal women. The single meta-analysis identified on
association of postmenopausal hormone replacement therapy
use and endometrial cancer incidence was excluded from this
umbrella due to a lack of study-specific data.160 Conducting
sensitivity analyses according to the histological subtype of
endometrial cancer was not possible, as this data was not pro-
vided in the individual studies, but is likely to be highly
relevant.
Conclusions
This umbrella review provides a comprehensive summary of
the body of published systematic reviews and meta-analyses
examining risk factors and the incidence and mortality from
endometrial cancer. There is a strong association between BMI
(per 5 kg/m2) and waist-to-hip ratio (per 0.1 unit) and an
increased risk of pre-menopausal and total endometrial cancer,
respectively. A reduced risk of endometrial cancer in parous
versus nulliparous women is also strongly associated. Although
there are other exposures which may be associated with an
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increased or decreased risk of this cancer, their association is
less certain and firm conclusions cannot be drawn at this time.
The identification of risk factors that are robustly associ-
ated with risk of endometrial cancer can help the identifica-
tion of high-risk groups of women that would benefit from
targeted prevention strategies. Our findings emphasise that
obesity is a major risk factor for endometrial cancer and high-
lights the importance of weight control programs in mitigat-
ing the further rise in incidence of this malignancy. Hormonal
and metabolic pathways that underlie the association of adi-
posity with endometrial cancer, as well as for diabetes and
parity, require further characterisation as they may offer
potential targets for preventive strategies in higher risk
women.
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